Pair Name	Hederagenin, Cisplatin
Disease Info	Head and neck cancer			/
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	HMOX1	hsa3162
	Up-regulation	Expression	KEAP1	hsa9817
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	NQO1	hsa1728
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	SLC7A11	hsa23657
	Down-regulation	Expression	SQSTM1	hsa8878
	Up-regulation	Phosphorylation	TP53	hsa7157
In Vitro Model	HN-3	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_8126
	HN-9	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_8132
	HN3-cisR	Cisplatin-resistant tongue squamous cell carcinoma	Homo sapiens (Human)	N.A.
	HN9-cisR	Cisplatin-resistant tongue squamous cell carcinoma	Homo sapiens (Human)	N.A.
In Vivo Model	HN9-cisR cells were subcutaneously injected into the flank of nude mice. Beginning on the first day gross nodules from tumor implants were detected, the mice began receiving intraperitoneal injections of the vehicle control or hederagenin (50, 100, or 200 mg/kg daily). Each treatment group included 10 mice.
Result	Hederagenin effectively targets cisplatin-resistant HNC cells in vitro and in vivo. Consistent with its effects in other types of cancer, hederagenin markedly induces apoptosis in HNC cells by activating the mitochondria-driven intrinsic apoptotic pathway. We demonstrated that the apoptosis-inducing effects of hederagenin are mediated by the inhibition of the Nrf2-ARE antioxidant pathway.